Christophe De Block - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Filters

Christophe De Block

Showing results (141-150 of 141) with videos related to

Pageof 15

Sort By:

You have reached the last page of results.This site can display upto 141 results.

Lancet (London, England)|September 21, 2025

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.

Pageof 15

Search research articles

Showing results (141-150 of 141) with videos related to

Sort By:

Pageof 15

You have reached the last page of results.This site can display upto 141 results.

Lancet (London, England)|September 21, 2025

Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trialChantal Mathieu, Julie Wych, A Emile J Hendriks, et al.

Pageof 15